Hemophagocytic Lymphohistiocytosis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Hemophagocytic Lymphohistiocytosis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemophagocytic Lymphohistiocytosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hemophagocytic Lymphohistiocytosis: Overview
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition caused by an overactive, abnormal response of the immune system. The immune system is the body’s natural defense system against foreign or invading organisms or substances. Hemophagocytic lymphohistiocytosis (HLH) is a condition with different underlying causes. There are several names used to describe this condition. Familial hemophagocytic lymphohistiocytosis (FHL) refers to genetic forms that are caused by an abnormal variant in a gene.
Hemophagocytic lymphohistiocytosis is broadly broken down into primary and secondary (acquired) forms. The condition results from an ineffective, abnormal response of the immune system to a stimulus or ‘trigger’. A diagnosis is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. The treatment of hemophagocytic lymphohistiocytosis is directed toward the specific symptoms that are apparent in each individual. Gamifant (emapalumab) was approved for the treatment of pediatric and adult patients with primary HLH who have refractory, recurrent or progressive disease or cannot tolerate conventional HLH therapy.
Report Highlights
This segment of the Hemophagocytic Lymphohistiocytosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hemophagocytic Lymphohistiocytosis Emerging Drugs
Further product details are provided in the report……..
Hemophagocytic Lymphohistiocytosis: Therapeutic Assessment
This segment of the report provides insights about the different Hemophagocytic Lymphohistiocytosis drugs segregated based on following parameters that define the scope of the report, such as:
Hemophagocytic Lymphohistiocytosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hemophagocytic Lymphohistiocytosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemophagocytic Lymphohistiocytosis drugs.
Hemophagocytic Lymphohistiocytosis Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Hemophagocytic Lymphohistiocytosis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemophagocytic Lymphohistiocytosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hemophagocytic Lymphohistiocytosis: Overview
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition caused by an overactive, abnormal response of the immune system. The immune system is the body’s natural defense system against foreign or invading organisms or substances. Hemophagocytic lymphohistiocytosis (HLH) is a condition with different underlying causes. There are several names used to describe this condition. Familial hemophagocytic lymphohistiocytosis (FHL) refers to genetic forms that are caused by an abnormal variant in a gene.
Hemophagocytic lymphohistiocytosis is broadly broken down into primary and secondary (acquired) forms. The condition results from an ineffective, abnormal response of the immune system to a stimulus or ‘trigger’. A diagnosis is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. The treatment of hemophagocytic lymphohistiocytosis is directed toward the specific symptoms that are apparent in each individual. Gamifant (emapalumab) was approved for the treatment of pediatric and adult patients with primary HLH who have refractory, recurrent or progressive disease or cannot tolerate conventional HLH therapy.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hemophagocytic Lymphohistiocytosis R&D. The therapies under development are focused on novel approaches for Hemophagocytic Lymphohistiocytosis.
This segment of the Hemophagocytic Lymphohistiocytosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hemophagocytic Lymphohistiocytosis Emerging Drugs
- Tabelecleucel: Atara Biotherapeutics
- TQ05105: Chia Tai Tianqing Pharmaceutical Group
Further product details are provided in the report……..
Hemophagocytic Lymphohistiocytosis: Therapeutic Assessment
This segment of the report provides insights about the different Hemophagocytic Lymphohistiocytosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Hemophagocytic Lymphohistiocytosis
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Hemophagocytic Lymphohistiocytosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hemophagocytic Lymphohistiocytosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemophagocytic Lymphohistiocytosis drugs.
Hemophagocytic Lymphohistiocytosis Report Insights
- Hemophagocytic Lymphohistiocytosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Hemophagocytic Lymphohistiocytosis drugs?
- How many Hemophagocytic Lymphohistiocytosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Hemophagocytic Lymphohistiocytosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemophagocytic Lymphohistiocytosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hemophagocytic Lymphohistiocytosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chia Tai Tianqing Pharmaceutical Group
- Bellicum Pharmaceuticals
- Atara Biotherapeutics
- Incyte Corporation
- Alpine Immune Sciences
- Expression Therapeutics
- TQ05105
- BPX-501
- Tabelecleucel
- Ruxolitinib
- ALPN-101
- Autologous gene therapy
Introduction
Executive Summary
Hemophagocytic Lymphohistiocytosis: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tabelecleucel: Atara Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TQ05105: Chia Tai Tianqing Pharmaceutical Group Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
ALPN-101: Alpine Immune Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hemophagocytic Lymphohistiocytosis Key Companies
Hemophagocytic Lymphohistiocytosis Key Products
Hemophagocytic Lymphohistiocytosis- Unmet Needs
Hemophagocytic Lymphohistiocytosis- Market Drivers and Barriers
Hemophagocytic Lymphohistiocytosis- Future Perspectives and Conclusion
Hemophagocytic Lymphohistiocytosis Analyst Views
Hemophagocytic Lymphohistiocytosis Key Companies
Appendix
Executive Summary
Hemophagocytic Lymphohistiocytosis: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tabelecleucel: Atara Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TQ05105: Chia Tai Tianqing Pharmaceutical Group Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
ALPN-101: Alpine Immune Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hemophagocytic Lymphohistiocytosis Key Companies
Hemophagocytic Lymphohistiocytosis Key Products
Hemophagocytic Lymphohistiocytosis- Unmet Needs
Hemophagocytic Lymphohistiocytosis- Market Drivers and Barriers
Hemophagocytic Lymphohistiocytosis- Future Perspectives and Conclusion
Hemophagocytic Lymphohistiocytosis Analyst Views
Hemophagocytic Lymphohistiocytosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hemophagocytic Lymphohistiocytosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hemophagocytic Lymphohistiocytosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hemophagocytic Lymphohistiocytosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hemophagocytic Lymphohistiocytosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
